Cancer Cell
Volume 23, Issue 2, 11 February 2013, Pages 143-158
ArticleLKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin
Under an Elsevier user license
open archive
Highlights
► Phenformin is a mitochondrial inhibitor that selectively kills LKB1−/− NSCLC cells ► LKB1−/− NSCLC cells exhibit defective mitochondria and ROS following phenformin ► Phenformin improves tumors and survival in KrasG12DLkb1−/−, not KrasG12Dp53−/− mice ► eIF2α signaling markers are AMPK-independent biomarkers of biguanide treatment
Cited by (0)
- 6
Present address: Laboratory of Molecular Pathology, Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA 92093, USA
Copyright © 2013 Elsevier Inc. All rights reserved.